Phase 3 Clinical Trial Comparing the Efficacy of an Investigational Medication Combined with Daratumumab or Daratumumab and Pomalidomide Versus Daratumumab, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma. MONUMENTAL-3

What's the purpose of this trial?

The goal of this clinical trial is to learn more about the efficacy of an investigational medication when combined with either Daratumumab and Pomalidomide or Daratumumab alone, and compare the efficacy to another regimen, Daratumumab, Pomalidomide and Dexamethasone. 

This trial is currently open and accepting patients.

What will happen during the trial?

This trial is organized into 28-day cycles. Participants in this trial will be randomly assigned in to one of three different groups, or arms. Participants in all arms may receive pre-treatment medications to help minimize the risk of side effects from the study drugs.

Treatment Involved

The investigational medication being studied is a type of drug called a bispecific antibody. Bispecific antibodies are drugs that have two different targets. This investigational medication’s two targets are CD3, a receptor found on our own T cells, and GPRC5D, a protein found on the surface of some myeloma cells. The investigational medication is being evaluated to determine if once in the body, it will draw the body’s T cells and myeloma cells closer together, resulting in T cell activation and myeloma cell death. 

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

  • have received at least one prior line of therapy, including a proteasome inhibitor and lenalidomide.
  • participants with only one line must be refractory to lenalidomide.
  • are not refractory to an anti-CD38 monoclonal antibody.
  • have not previously had treatment with any GPRC5D targeted therapy or Pomalidomide.
  • have not had an allogeneic stem cell transplant in the last six months, or an autologous stem cell transplant in the last three months.
  • do not have active autoimmune disease or history of autoimmune disease in the last two years. 

Additional Trial Information

Phase 3

Enrollment: 810 patients (estimated)

View More

Trial Links

Read the latest news and updates on this trial.

Multiple Myeloma in Clinical Trials

September 26, 2022

Click below to watch a short video about Multiple Myeloma clinical trial participation.

Read more

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.


University of Arizona Cancer Center North Campus

Tucson, AZ

Not Yet Accepting


University of Arkansas for Medical Sciences (UAMS)

Little Rock, AR

Open and Accepting


Whittingham Cancer Center at Norwalk Hospital Nuvance Health

Norwalk, CT

Open and Accepting



University of Illinois at Chicago

Chicago, IL

Not Yet Accepting


University of Kansas Cancer Center

Kansas City, KS

Not Yet Accepting


Ochsner Medical Complex (The Grove)

Baton Rouge, LA

Not Yet Accepting

Tulane Cancer Center Tulane University School of Medicine

New Orleans, LA

Not Yet Accepting


Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Medicine

Baltimore, MD

Not Yet Accepting


Massachusetts General Hospital

Boston, MA

Not Yet Accepting

University of Massachusetts Medical School

Worcester, MA

Open and Accepting


University of Michigan Comprehensive Cancer Center Rogel Cancer Center

Ann Arbor, MI

Not Yet Accepting


University of Mississippi Medical Center

Jackson, MS

Not Yet Accepting


Alvin J. Siteman Cancer Center Washington University Medical Campus

St. Louis, MO

Not Yet Accepting

New York

North Carolina

UNC Lineberger Comprehensive Cancer Center University of North Carolina

Chapel Hill, NC

Open and Accepting

Wake Forest Baptist Atrium Health

Winston-Salem, NC

Not Yet Accepting

Levine Cancer Institute Atrium Health

Charlotte, NC

Not Yet Accepting


OhioHealth Riverside Methodist Hospital

Columbus, OH

Not Yet Accepting


Thomas Jefferson University Hospital

Philadelphia, PA

Open and Accepting


Baptist Cancer Center Memphis

Mempis, TN

Open and Accepting


Houston Methodist Hospital

Houston, TX

Open and Accepting


Huntsman Cancer Institute University of Utah

Salt Lake City, UT

Not Yet Accepting


Massey Cancer Center Virginia Commonwealth University (VCU Health)

Richmond, VA

Not Yet Accepting


Seattle Cancer Care Alliance SCCA

Seattle, WA

Open and Accepting

Washington, D.C.

MedStar Georgetown University Hospital

Washington, DC

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

Learn more about how we work with trial sponsors